Mark E. Dmytruk - 13 Mar 2025 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role
Chief Financial Officer
Signature
/s/ Karen Tepichin, Attorney-in-Fact
Issuer symbol
DNA
Transactions as of
13 Mar 2025
Net transactions value
$0
Form type
4
Filing time
17 Mar 2025, 16:32:07 UTC
Previous filing
10 Mar 2025
Next filing
23 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNA Class A Common Stock Conversion of derivative security $0 +9,497 +27% $0.000000 44,149 13 Mar 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNA Class B Common Stock Conversion of derivative security $0 -9,497 -62% $0.000000 5,914 13 Mar 2025 Class A Common Stock 9,497 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.
F2 Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

Remarks:

Chief Financial Officer